The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 56 | — | 20.3x | Near average | |
Growth | 7 | — | 5.6% | Below average | |
Quality | 4 | -345.1% | 7.6% | Below average | |
Safety | 71 | 0.2x | 0.4x | Above average | |
Capital Return | 41 | — | 2.15% | Near average | |
Momentum | 21 | — | — | Below average | |
Sentiment | 85 | — | — | Above average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Summit Therapeutics Inc. (listed under the ticker SMMT on NASDAQ) is a specialized biopharmaceutical company dedicated to improving the lives of cancer patients through the development and commercialization of innovative therapies. The company's investment and operational value is primarily centered around its lead drug candidate, ivonescimab, a bispecific antibody targeting both PD-1 and vascular endothelial growth factor (VEGF). The company realizes its current market value of $11.5 billion by developing this drug as a promising therapeutic platform through strategic partnerships, particularly with the Chinese company Akeso, which originally created this compound, aiming to introduce the drug in multiple combination therapies to combat solid tumors.
On the financial side and regarding recent quarterly results, reports released for the third quarter of 2024 showed zero revenue and gross profit, which is typical for biopharmaceutical companies in pre-commercial clinical development stages. The company recorded a net loss of $56.3 million in the third quarter of 2024 (equivalent to a loss of $0.08 per share), compared to a net loss of $21.3 million ($0.03 per share) in the third quarter of 2023. On an annual basis for 2024, the company's net loss amounted to $221.3 million (a loss of $0.31 per share), compared to a loss of $614.9 million ($0.99 per share) in the fiscal year 2023. At the end of the fiscal year 2025, the company concluded its year with a strong cash position of $713.4 million, with its records completely free of debt.
Summit Therapeutics stock is currently trading at a price of $14.77, which is below the lowest target price set by analysts of $16. The stock also trades below the analyst consensus average target price of $19, while the highest future target price reaches $23. Based on this consensus, which recommends a "Buy", the stock possesses a good upside opportunity to reach target levels.
The US Food and Drug Administration (FDA) has set November 14, 2026, as the action date (PDUFA) for the Biologics License Application (BLA) for ivonescimab. This approval target is for the use of the drug as a treatment for patients with EGFR-mutated non-small cell lung cancer after undergoing TKI therapy. Summit Therapeutics is currently accelerating its commercial and medical preparations to ensure a successful launch of the drug immediately upon obtaining approval in the fourth quarter of 2026.
The company announced the completion of patient screening for the 600-patient Squamous Cohort in the HARMONi-3 trial, with the randomization of the last patient expected within the next few weeks. The company amended the statistical plan to conduct an interim progression-free survival (PFS) analysis for this cohort during the second quarter of 2026. As for the non-squamous cohort, patient enrollment is expected to be completed in the second half of 2026, with final PFS data anticipated in the first half of 2027.
The company's clinical decisions were based on robust results from the HARMONi-2 trial, which compared ivonescimab to pembrolizumab and demonstrated a statistically significant superiority with a Hazard Ratio of 0.51 and an improvement in median PFS of more than 5 months. This superiority was also confirmed in the HARMONi-6 trial, which compared the drug plus chemotherapy versus PD-1 inhibitors plus chemotherapy, recording a Hazard Ratio of 0.60. These data illustrate the high efficiency of the drug's dual mechanism of action in improving patient outcomes.
Automated analysis for informational purposes only — not investment advice.
The company announced its collaboration with the French cooperative group GORTEC to launch the Phase III ILLUMINE study for the treatment of head and neck cancer using ivonescimab as a monotherapy or in combination with ligufalimab. The company also initiated dosing of the first patient in its joint study with Revolution Medicines to evaluate the drug's combination with three RAS inhibitors. Additionally, the company plans to start a clinical trial in mid-2026 in collaboration with GSK to combine ivonescimab with targeted antibodies for the treatment of small cell lung cancer and other solid tumors.